|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-8-12
|
|
pubmed:abstractText |
European Group for Blood and Marrow Transplantation (EBMT) registry data indicate that patients with relapsed HD given high-dose therapy (HDT), supported with PBPC might have a poorer outcome compared with those given BM. Since this can be due to the infusion of contaminating tumor cells in the PBPC products, we studied the presence of minimal residual disease and tested whether CD34(+) cell enrichment was able to remove atypical CD30(+) cells from PBPC grafts.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1465-3249
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
295-305
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12171718-Adolescent,
pubmed-meshheading:12171718-Adult,
pubmed-meshheading:12171718-Antigens, CD30,
pubmed-meshheading:12171718-Antigens, CD34,
pubmed-meshheading:12171718-Biological Markers,
pubmed-meshheading:12171718-Bone Marrow Cells,
pubmed-meshheading:12171718-Child,
pubmed-meshheading:12171718-Female,
pubmed-meshheading:12171718-Graft Survival,
pubmed-meshheading:12171718-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12171718-Hodgkin Disease,
pubmed-meshheading:12171718-Humans,
pubmed-meshheading:12171718-Immunohistochemistry,
pubmed-meshheading:12171718-Immunomagnetic Separation,
pubmed-meshheading:12171718-Lymphocytes,
pubmed-meshheading:12171718-Male,
pubmed-meshheading:12171718-Middle Aged,
pubmed-meshheading:12171718-Neoplastic Cells, Circulating,
pubmed-meshheading:12171718-Platelet Transfusion,
pubmed-meshheading:12171718-Recurrence,
pubmed-meshheading:12171718-Survival Rate,
pubmed-meshheading:12171718-Treatment Outcome,
pubmed-meshheading:12171718-Tumor Markers, Biological
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
|
|
pubmed:affiliation |
Department of Oncology, The Norwegian Radium Hospital, Oslo, Norway.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
